Abnormal vaginal bleeding is a symptom that should never be ignored. For one Malaysian patient, Ms. Lee, what initially seemed like a gynecological issue eventually led to the diagnosis of an extremely rare cancer: primary fallopian tube squamous cell carcinoma.
Her journey from Malaysia to Guangzhou, China reflects the importance of timely diagnosis, multidisciplinary evaluation, and personalized cancer treatment for international patients.
From Abnormal Bleeding to a Rare Cancer Diagnosis
Ms. Lee first noticed unexplained vaginal bleeding and visited a private doctor in Malaysia. After gynecological examination and cervical conization, her pathology report showed CIN III, also known as severe cervical dysplasia or carcinoma in situ of the cervix.
At that time, her doctor recommended a hysterectomy to prevent further progression. However, because the bleeding had stopped and she did not fully understand the seriousness of the condition, Ms. Lee chose to delay surgery.
Several months later, the bleeding returned. This time, she underwent total hysterectomy with bilateral salpingo-oophorectomy. The postoperative pathology report revealed a more serious condition:
- Well-differentiated keratinizing squamous cell carcinoma of the cervix
- Moderately differentiated squamous cell carcinoma in the right fallopian tube
- Tumor invasion extending to the right ovary
- Evidence suggesting primary fallopian tube squamous cell carcinoma
Primary fallopian tube carcinoma is already rare, accounting for a very small proportion of female genital tract malignancies. Squamous cell carcinoma of the fallopian tube is even rarer.
Why Fallopian Tube Cancer Is Difficult to Detect Early
Fallopian tube cancer can be difficult to diagnose in its early stages because symptoms are often nonspecific. It may be mistaken for gynecological inflammation, ovarian disease, or other pelvic conditions.
Patients should seek medical attention if they experience symptoms such as:
- Unexplained abnormal vaginal bleeding or discharge
- Persistent lower abdominal or pelvic pain
- Unexplained pelvic mass
- Abdominal bloating
- Urinary frequency
- Unexplained weight loss
Early evaluation is especially important for postmenopausal women or patients with recurrent abnormal bleeding.
Recurrence After Surgery and Chemotherapy
After surgery, Ms. Lee received six cycles of chemotherapy combined with targeted therapy. For a period of time, follow-up examinations showed no obvious tumor recurrence or metastasis.
However, in August and September 2025, two follow-up tests showed elevated CEA tumor marker levels. Further examination found small mesenteric lymph nodes and thickening of the right vaginal wall. Her doctor suspected recurrence.
This was a difficult moment for Ms. Lee. After completing another cycle of chemotherapy, she was physically weak and emotionally uncertain. At that time, a close friend introduced her to a public medical lecture related to cancer treatment in China.
After learning more and comparing different hospitals, Ms. Lee decided to seek further treatment in Guangzhou.
Seeking Treatment at Fuda Cancer Hospital in Guangzhou
In October 2025, Ms. Lee arrived in Guangzhou, China, and was admitted to the Fourth Department of Medicine at Fuda Cancer Hospital.
After admission, the hospital’s multidisciplinary team, also known as an MDT, reviewed her case carefully. Her pathology was re-examined and evaluated in detail. The final assessment was:
Recurrent stage IIIA2 right fallopian tube squamous cell carcinoma after surgery.
One important test result attracted the team’s attention: her PD-L1 immunohistochemistry TPS was ≥ 50%. This suggested that immunotherapy, particularly PD-1/PD-L1-related treatment, might be a potential option after comprehensive evaluation.
Personalized Treatment: TAI Combined with Immunotherapy
After multidisciplinary discussion, the medical team customized a treatment plan for Ms. Lee:
Transarterial Infusion Chemotherapy, also known as TAI, combined with immunotherapy.
TAI is a treatment method that delivers chemotherapy drugs directly into the arteries supplying the tumor area. Compared with conventional systemic chemotherapy, this approach may help increase the local drug concentration around the tumor while reducing some systemic side effects.
Immunotherapy works differently. Instead of directly attacking the tumor like chemotherapy, it helps activate the patient’s own immune system so immune cells can better recognize and attack cancer cells.
In Ms. Lee’s case, the treatment strategy combined local intervention with systemic immune support.
Encouraging Follow-Up Results
After six treatment cycles, Ms. Lee’s follow-up results showed encouraging changes:
- PET-CT showed no obvious signs of hypermetabolic malignant tumors
- Tumor remission was observed
- Tumor markers decreased to normal levels
These results suggested that the treatment was effective. Ms. Lee has continued maintenance therapy and follow-up care to help protect the progress she has achieved.
Her story is not simply about a “miracle.” It is about a patient who continued searching for treatment options during a difficult period and found a personalized approach through multidisciplinary care.
What International Patients Can Learn from This Case
Ms. Lee’s experience highlights several important points for cancer patients and families:
First, abnormal vaginal bleeding should not be ignored, especially when it happens repeatedly or after menopause.
Second, rare cancers often require careful pathological review and multidisciplinary consultation.
Third, for recurrent or complex cancer cases, personalized treatment planning may provide additional options beyond standard therapy.
Finally, international patients seeking cancer treatment in China should look for hospitals with multidisciplinary teams, experience in complex cases, and international patient support services.
About Fuda Cancer Hospital
Fuda Cancer Hospital, located in Guangzhou, China, provides cancer diagnosis and treatment services for both local and international patients. The hospital’s multidisciplinary teams evaluate complex cancer cases and design personalized treatment plans based on each patient’s condition, pathology, imaging results, tumor markers, and overall health status.
For international patients, coordinated medical support can help make the process of consultation, admission, treatment, and follow-up more manageable.
FAQ
What is fallopian tube cancer?
Fallopian tube cancer is a rare gynecological malignancy that starts in the fallopian tubes. Because early symptoms are often unclear, it may be difficult to diagnose at an early stage.
Is fallopian tube squamous cell carcinoma common?
No. Primary fallopian tube carcinoma itself is rare, and squamous cell carcinoma of the fallopian tube is an even rarer subtype.
What symptoms should patients pay attention to?
Patients should pay attention to abnormal vaginal bleeding, abnormal discharge, pelvic pain, abdominal bloating, pelvic mass, urinary frequency, or unexplained weight loss.
What treatment did the patient receive at Fuda Cancer Hospital?
According to the case, the patient received multidisciplinary evaluation followed by transarterial infusion chemotherapy combined with immunotherapy.
Can every patient receive the same treatment?
No. Cancer treatment must be based on the patient’s diagnosis, stage, pathology, biomarkers, imaging results, previous treatments, and overall physical condition. Patients should consult qualified medical professionals before making treatment decisions.
Medical Disclaimer
This article is for health education and case-sharing purposes only. It should not be used as a substitute for professional medical diagnosis or treatment. Individual treatment results may vary. Patients should consult qualified doctors for personalized medical advice.